About 100 antidotes to corona are being tested. The most advanced of these is the antidote ChAdOx1 nCoV-19 developed by researchers at Oxford University. This time the production of this antidote started.
The British pharmaceutical giant AstraZeneca has begun production of the drug, developed by researchers at Oxford University. In an interview with BBC Radio on Friday, Pascal Sariot, the company’s chief executive, said:
This ChAdOx1 nCoV-19 antidote from Oxford is already on the verge of ultimate success. On April 23, researchers at the University of Oxford experimented with coronavirus on humans. The effectiveness of ChAdOx1 nCoV-19 was tested on 510 volunteers. The 1,000 human volunteers who did not make it to the finals in Brazil will be subjected to a “human trial” of Oxford’s ChAdOx1 nCoV-19 antidote. That’s what the Federal University of Sওo Paulo said.
The results of the final episode of Oxford’s Corona Ticker will be available in July! After that the speed of production will be further increased. AstraZeneca has contracted with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance and the Serum Institute of India.
Read more: The final episode will be over 1000 people in Brazil! Oxford coronary vaccine awaiting application
After unprecedented success in the first two human trials, British pharmaceutical giant AstraZeneca is quite optimistic about the success of the final phase of the antidote ChAdOx1 nCoV-19, developed by researchers at the University of Oxford. Keeping in mind the situation that is getting worse, the company is already starting the work of vaccine production in a preliminary way. Ticker production will be increased later in July after the final results are known. According to the agency, if all goes well, preparations have started with the target of bringing at least 200 crore doses of this antidote to the world market by next September.